Analyzer suits low- to mid- volume immunoassay market.
Press Release Summary:
Operating independently, as dedicated STAT analyzer, or as part of networked clinical laboratory environment, cobas e 411 analyzer provides results for critical assays Troponin T, CK-MB, Myoglobin, and HCG in 9 minutes. Electrochemiluminescence (ECL) delivers low-end sensitivity and broad dynamic range, and eliminates unnecessary repeats and reruns by providing accurate results first time. Product delivers high level of accuracy and efficiency for IA testing.
Original Press Release:
Roche Diagnostics Announces the Launch of the cobas e 411 Analyzer
Setting new standards in immunoassay diagnostics
INDIANAPOLIS, Jan. 8 /- Roche Diagnostics today announced that it has released for sale its next generation bench-top immunoassay analyzer, the cobas e 411 analyzer. This analyzer will be an integral part of Roche's immunoassay portfolio and is an ideal solution for the low- to mid- volume immunoassay market. The cobas e 411 analyzer optimizes operational efficiency by combining fast turnaround time and ease of use with proven, reliable Elecsys system technology.
"Roche Diagnostics is committed to being the leader in the immunoassay market. The cobas e 411 analyzer is evidence of our strength in innovation to provide greater efficiency and increased productivity in the laboratory," Andy Thomson, Senior Vice President and General Manager, Roche Centralized Diagnostics said. "When labs rely on the cobas e 411 analyzer, they can have confidence in every immunoassay result."
The cobas e 411 analyzer is the perfect analyzer to operate independently, as a dedicated STAT analyzer, or as part of a networked clinical laboratory environment. The cobas e 411 analyzer provides results for critical assays - Troponin T, CK-MB, Myoglobin, and HCG - in as little as nine minutes. The heart of the cobas e 411 analyzer-and unique to all Roche Diagnostics immunoassay analyzers-is electrochemiluminescence or ECL. As a detection system, ECL technology delivers excellent low-end sensitivity and a broad dynamic range. It virtually eliminates unnecessary repeats and reruns, providing accurate results the first time.
Following on the heels of the recent successful launch of the cobas 6000 analyzer series, the cobas e 411 analyzer is the latest member of the cobas instrument platform. The cobas instrument platform concept consists of more than just analytical components. It has been designed to help labs reduce the complexity around chemistry and immunochemistry testing, leading to real efficiency improvements. This is accomplished through a standardized graphical user-interface, common assay applications and technologies, and uniform reagent carriers across analytical systems.
The cobas e 411 analyzer, along with all Roche Diagnostics immunoassay analyzers, provides the highest level of accuracy, quality, and efficiency for IA testing. From the unique ECL technology detection system, to innovative software and hardware, the cobas e 411 analyzer delivers confidence in every result.
About Roche and the Roche Diagnostics Division
Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As a supplier of innovative products and services for the early detection, prevention, diagnosis and treatment of disease, the Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is a world leader in diagnostics, the leading supplier of medicines for cancer and transplantation and a market leader in virology. In 2005, sales by the Pharmaceuticals Division totalled 27.3 billion Swiss francs, and the Diagnostics Division posted sales of 8.2 billion Swiss francs. Roche employs roughly 70,000 people in 150 countries and has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai. Roche's Diagnostics Division offers a uniquely broad product portfolio and supplies a wide array of innovative testing products and services to researchers, physicians, patients, hospitals and laboratories world-wide. For further information, please visit our websites www.roche.com and www.roche-diagnostics.us
For further information please contact:
Doyia Turner
Corporate Communications
Phone: 317-521-7252
e.mail: doyia.turner@roche.com
Source: Roche Diagnostics
Web site: www.roche.com/
http://www.roche-diagnostics.us/
